Evidence‑Based Management of Dyspepsia

Initial Evaluation and Risk Stratification

• Urgent endoscopy is indicated for adults ≥ 55 years presenting with dyspepsia plus weight loss, or for those > 40 years from high‑gastric‑cancer‑risk regions or with a family history of gastro‑oesophageal cancer (British Society of Gastroenterology, strong recommendation) 1.
• Non‑urgent endoscopy should be considered in adults ≥ 55 years with dyspepsia that is resistant to initial therapy, or when associated with thrombocytosis, nausea, or vomiting (British Society of Gastroenterology, conditional recommendation) 2.
• For adults ≥ 60 years with abdominal pain and weight loss, an urgent abdominal CT scan is recommended to exclude pancreatic malignancy (British Society of Gastroenterology) 2.
• A complete blood count should be obtained in all patients ≥ 55 years with dyspepsia (British Society of Gastroenterology) 3.
• Coeliac serology is advised for patients with functional dyspepsia who also have irritable‑bowel‑syndrome‑type symptoms (British Society of Gastroenterology) 2.
• Patients whose predominant symptom is frequent heartburn/acid regurgitation (≥ once weekly) should be classified and managed as gastro‑oesophageal reflux disease rather than dyspepsia (American College of Gastroenterology, strong recommendation) 4.

First‑Line Diagnostic and Therapeutic Strategy

H. pylori Test‑and‑Treat

• All adults without alarm features should undergo non‑invasive H. pylori testing (¹³C‑urea breath test or stool antigen) (British Society of Gastroenterology) 1.
• If H. pylori‑positive, eradication therapy is mandatory and provides high‑quality, strong‑evidence benefit for functional dyspepsia (British Society of Gastroenterology) 5.
• Post‑treatment confirmation of eradication is required only for patients at increased gastric‑cancer risk (British Society of Gastroenterology) 1.
• In populations where H. pylori prevalence ≤ 10 %, empirical proton‑pump inhibitor (PPI) therapy is more cost‑effective than test‑and‑treat, although the latter may still prevent future gastric adenocarcinoma (American College of Gastroenterology) 4.

Empirical Acid Suppression

• For H. pylori‑negative patients or those with persistent symptoms after eradication, prescribe a PPI for 4–8 weeks at the lowest dose that controls symptoms (British Society of Gastroenterology, strong recommendation) 2.
• PPIs achieve strong symptom relief without a dose‑response relationship; low‑dose regimens are therefore appropriate and cost‑effective (British Society of Gastroenterology) 5.
• H₂‑receptor antagonists may be used as an alternative, but the supporting evidence is weaker (weak recommendation, low‑quality evidence) (British Society of Gastroenterology) 6.

Lifestyle and Supportive Measures

• Regular aerobic exercise is recommended for all patients with functional dyspepsia (strong recommendation) (British Society of Gastroenterology) 6.
• Patients should be advised to avoid foods that individually trigger their symptoms; however, formal dietary regimens such as low‑FODMAP lack sufficient evidence for routine use (British Society of Gastroenterology) 7.

Second‑Line (Refractory) Pharmacologic Therapy

• Tricyclic antidepressants (TCAs) are the most effective second‑line agents for functional dyspepsia, supported by strong evidence (British Society of Gastroenterology) 2.
• Initiate amitriptyline at 10 mg nightly and titrate slowly to a maximum of 30–50 mg daily based on symptom response (British Society of Gastroenterology) 5.
• Counsel patients that TCAs are prescribed for pain modulation and gut‑brain axis effects, not for depression, and discuss common side effects (dry mouth, constipation, drowsiness) (British Society of Gastroenterology) 6.
• Antipsychotic agents such as sulpiride (100 mg four times daily) or levosulpiride (25 mg three times daily) may be effective, but require careful patient counseling regarding rationale and adverse effects (British Society of Gastroenterology) 5.

Multidisciplinary Management of Severe or Refractory Cases

• A multidisciplinary team—including gastroenterology, dietetics, and mental‑health services—should be engaged for patients with severe or refractory functional dyspepsia (British Society of Gastroenterology, strong recommendation) 8.
• Referral to specialized functional dyspepsia clinics that provide expert clinicians, dietary support, effective pharmacotherapy, and gut‑brain behavioural therapies is advised (British Society of Gastroenterology) 2.
• Opioids and surgical interventions should be avoided in severe/refractory functional dyspepsia to minimize iatrogenic harm (strong recommendation) (British Society of Gastroenterology) 8.
• Screen individuals presenting with weight loss and restrictive eating patterns for eating‑disorder phenotypes such as avoidant‑restrictive food intake disorder (ARFID) (British Society of Gastroenterology) 8.
• Early involvement of a dietitian is essential to prevent overly restrictive diets that could worsen nutritional status (British Society of Gastroenterology) 8.

Procedures and Tests Not Recommended in Typical Functional Dyspepsia

• Routine gastric emptying studies and 24‑hour oesophageal pH monitoring are not indicated for patients with classic functional dyspepsia symptoms (British Society of Gastroenterology) 2.

Clinical Pitfalls and Safety Considerations

• Do not automatically refer patients < 55–60 years with alarm features for endoscopy; assess the severity and number of alarm symptoms on a case‑by‑case basis (British Society of Gastroenterology) 3.
• The majority of dyspepsia patients undergoing endoscopy have functional dyspepsia (> 50 %); organic disease such as peptic ulcer is found in only ≈ 10 % (American College of Gastroenterology, strong evidence) 4.
• Higher‑dose PPI regimens do not improve outcomes in non‑responders; escalation should proceed to neuromodulator therapy (British Society of Gastroenterology) 5.

Evidence‑Based Recommendations for Dyspepsia Diagnosis and Management

Diagnosis and Initial Assessment

• Functional dyspepsia (FD) is diagnosed clinically in patients with bothersome epigastric pain, burning, early satiation, or post‑prandial fullness lasting more than 8 weeks, provided no alarm features are present【9】【10】【11】【12】.
• FD is classified as a disorder of gut‑brain interaction; diet, stress, cognitive responses, and post‑infective changes influence symptoms【9】【10】【11】【12】.
• Establishing an empathic doctor‑patient relationship can reduce healthcare utilization and improve quality of life【9】【10】【11】【12】.

Indications for Endoscopy and Imaging

• Urgent endoscopy is indicated for patients ≥ 55 years with dyspepsia plus unexplained weight loss【9】【10】【11】【12】.
• Urgent endoscopy is also indicated for patients > 40 years who originate from high gastric‑cancer‑risk regions or have a family history of gastro‑oesophageal cancer【9】【10】【11】【12】.
• Non‑urgent endoscopy should be considered for patients ≥ 55 years with dyspepsia that is resistant to initial therapy【9】【11】【12】.
• Non‑urgent endoscopy is also considered for patients ≥ 55 years with dyspepsia accompanied by a raised platelet count, nausea, or vomiting【9】【11】【12】.
• Urgent abdominal CT is recommended for patients ≥ 60 years presenting with abdominal pain and weight loss to exclude pancreatic cancer【9】【10】【11】【12】.

Essential Laboratory Testing

• Perform a full blood count in all patients ≥ 55 years with dyspepsia【9】【10】【11】【12】.
• Conduct coeliac serology in all FD patients who have overlapping IBS‑type symptoms【9】【10】【11】【12】.

First‑Line Treatment

H. pylori Test‑and‑Treat

• All patients without alarm features should receive non‑invasive H. pylori testing (¹³C‑urea breath test or stool antigen)【9】【10】【12】.
• If H. pylori‑positive, eradication therapy is mandatory (strong recommendation, high‑quality evidence)【13】【14】.
• H. pylori eradication is highly efficacious for FD, although adverse events are more common than with control therapy【13】【14】.
• Post‑treatment confirmation of eradication is required only for patients at increased gastric‑cancer risk【10】【12】.

Empirical Acid Suppression

• For H. pylori‑negative patients or those with persistent symptoms after eradication, prescribe a proton‑pump inhibitor (PPI) for 4–8 weeks at the lowest effective dose (strong recommendation, high‑quality evidence)【13】【14】.
• PPIs demonstrate efficacy without a dose‑response relationship; higher doses do not improve outcomes in non‑responders【13】【14】.
• H₂‑receptor antagonists may be used as an alternative (weak recommendation, low‑quality evidence)【13】【14】.

Lifestyle Modifications

• Advise all patients to engage in regular aerobic exercise (strong recommendation)【13】.
• Recommend avoidance of individually identified trigger foods; routine use of formal dietary regimens (including low‑FODMAP) lacks sufficient evidence for standard care【13】【14】.

Prokinetic Therapy (Selected Cases)

• Certain prokinetics can be efficacious, especially for post‑prandial distress syndrome, though effectiveness varies by drug class【13】【14】.
• Tegaserod has moderate‑quality evidence supporting its use (strong recommendation); acotiamide, itopride, and mosapride have low‑quality evidence (weak recommendation)【13】【14】.
• Many prokinetic agents are unavailable outside Asia and the United States【13】【14】.

Second‑Line Treatment for Refractory FD

• Tricyclic antidepressants (TCAs) are the most effective second‑line agents (strong recommendation, moderate‑quality evidence)【13】【14】.
• Initiate amitriptyline at 10 mg once daily, titrating slowly to a maximum of 30–50 mg once daily based on symptom response【13】【14】.
• Counsel patients that TCAs are prescribed for gut‑brain neuromodulation and pain modulation, not for depression【13】【14】.
• Discuss common side effects (dry mouth, constipation, drowsiness)【13】【14】.
• TCAs may be started in primary or secondary care settings【13】【14】.

Alternative Second‑Line Options

• Antipsychotics may be efficacious: sulpiride 100 mg four times daily【13】【14】 or levosulpiride 25 mg three times daily【13】【14】.

Management of Severe or Refractory FD

• A multidisciplinary support team (including gastroenterology, dietetics, psychology) should be involved (strong recommendation, low‑quality evidence)【13】【14】.
• Opioids and surgical interventions should be avoided to minimize iatrogenic harm (strong recommendation)【13】【14】.
• Screen patients with weight loss and food restriction for eating disorders, including avoidant/restrictive food intake disorder (ARFID)【13】【14】.
• Early involvement of a dietitian is essential to prevent overly restrictive diets【13】【14】.

Management of Functional Dyspepsia in Adults

Diagnostic Approach

• Test all patients for Helicobacter pylori using non‑invasive methods (¹³C‑urea breath test or stool antigen). Strong recommendation. 15
• Perform urgent endoscopy in patients ≥55 years with dyspepsia plus weight loss, or in patients >40 years from high‑gastric‑cancer‑risk regions or with a family history of gastro‑oesophageal cancer. 16
• Consider non‑urgent endoscopy for patients ≥55 years with treatment‑resistant dyspepsia or dyspepsia accompanied by thrombocytosis, nausea, or vomiting. 16
• Obtain urgent abdominal CT in patients ≥60 years presenting with abdominal pain and weight loss to exclude pancreatic malignancy. Strong recommendation. [16][17]
• Do not routinely perform gastric emptying studies or 24‑hour pH monitoring in typical functional dyspepsia, as they add no diagnostic value. Strong recommendation. [15][16]17

First‑Line Pharmacologic Therapy

• Eradicate H. pylori in all infected patients; this intervention has strong, high‑quality evidence for symptom improvement. Strong recommendation. [15][16]17
• Confirm eradication only in patients at increased gastric‑cancer risk (family history or high‑risk ethnicity); routine confirmation is unnecessary. [15][16]17
• Prescribe a proton‑pump inhibitor (PPI) at the lowest dose that controls symptoms for 4–8 weeks. Strong recommendation, high‑quality evidence. [15][16]17
• Do not increase PPI dose in non‑responders; there is no dose‑response relationship and a different therapeutic class should be used. Strong recommendation. [15][16]17
• H₂‑receptor antagonists may be used as an alternative, but they have weaker supporting evidence (weak recommendation, low‑quality evidence). [15][16]17
• PPIs are effective regardless of functional dyspepsia subtype (epigastric pain syndrome vs. post‑prandial distress syndrome). 15

Lifestyle and Non‑Pharmacologic Measures

• Advise regular aerobic exercise for all patients. Strong recommendation. [15][16]17
• Recommend avoidance of individual trigger foods, but do not prescribe formal exclusion diets (e.g., low‑FODMAP) because evidence of benefit is insufficient. Strong recommendation. [15][16]17

Prokinetic Agents (Limited Role)

• Consider prokinetics primarily for the post‑prandial distress syndrome subtype; efficacy varies by drug class and most agents are unavailable outside Asia and the USA. [15][16]17
• Tegaserod has moderate‑quality evidence and receives a strong recommendation; acotiamide, itopride, and mosapride have low‑quality evidence and receive weak recommendations. [15][16]17

Second‑Line Pharmacologic Therapy (Refractory Symptoms)

• Initiate amitriptyline 10 mg nightly and titrate slowly to a maximum of 30–50 mg daily based on symptom response. Strong recommendation, moderate‑quality evidence. [15][16]17
• Counsel patients that tricyclic antidepressants are prescribed for gut‑brain neuromodulation and visceral pain modulation, not for depression. [15][16]17
• Inform patients about common side effects: dry mouth, constipation, and drowsiness. [15][16]17
• TCAs can be initiated in either primary‑care or secondary‑care settings. [15][16]17
• Evidence indicates that TCAs are the most effective second‑line pharmacologic option with the strongest evidence base for refractory functional dyspepsia. Strong recommendation. [15][16]17
• Antipsychotics (sulpiride or levosulpiride) may be efficacious but require careful counseling regarding rationale and adverse effects. [15][16]17

Multidisciplinary Management for Severe or Refractory Cases

• Engage a multidisciplinary team—including gastroenterology, dietetics, and mental‑health services—for patients with severe or refractory symptoms. Strong recommendation. [15][16]17
• Refer patients to specialized functional dyspepsia clinics that provide expert clinicians, dietary support, effective pharmacotherapy, and gut‑brain behavioral therapies. Strong recommendation. [15][16]17
• Involve a dietitian early to avoid overly restrictive diets that could worsen nutritional status. Strong recommendation. [15][16]17
• Screen for eating disorders (e.g., avoidant‑restrictive food intake disorder) in patients presenting with weight loss and food restriction. Strong recommendation. [15][16]17

Safety Recommendations

• Avoid opioids and surgical interventions in severe or refractory functional dyspepsia to minimize iatrogenic harm. Strong recommendation. [15][16]17

Common Pitfalls to Avoid

• Do not escalate PPI doses in non‑responders; instead, switch therapeutic class to a tricyclic antidepressant. Strong recommendation. [15][16]17
• Do not routinely order gastric emptying studies or 24‑hour pH monitoring, as they do not change management in typical functional dyspepsia. Strong recommendation. [15][16]17
• Do not prescribe formal exclusion diets without evidence of specific food intolerances. Strong recommendation. [15][16]17